Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25572999 | 0.83 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TAAR1CA12 | |
| SCHEMBL4031932 | 0.83 | POLB (0.69) | NPC1RAB9ASMN1; SMN2TAAR1CA12 | |
| SCHEMBL26333613 | 0.82 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2TAAR1CA12 | |
| SCHEMBL2731878 | 0.81 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL29145671 | 0.80 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TAAR1CA12 | |
| SCHEMBL4917108 | 0.80 | CA12 (0.65) | NPC1RAB9ASMN1; SMN2TAAR1CA12 | |
| SCHEMBL863136 | 0.79 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL28872246 | 0.78 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL17117234 | 0.77 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL4679645 | 0.77 | ADAM17 (0.55) | NPC1RAB9ASMN1; SMN2TAAR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-10-14 | — | — | US | disclosed |
| US-10995086-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-05-04 | — | — | US | disclosed |
| CN-111886233-A | Novel triazolone derivative or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2020-11-03 | — | — | CN | disclosed |
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAPB, VAT1 | NPC1 10/4885RAB9A 2039/4885SMN1; SMN2 2626/4885 |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAT1, LIPC | NPC1 20/4885RAB9A 2400/4885SMN1; SMN2 2498/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | NPC1 20/4885RAB9A 2400/4885SMN1; SMN2 2498/4885 |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | NPC1 296/4885RAB9A 571/4885SMN1; SMN2 95/4885 |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | NPC1 296/4885RAB9A 571/4885SMN1; SMN2 95/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | NPC1 296/4885RAB9A 571/4885SMN1; SMN2 95/4885 |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | NPC1 296/4885RAB9A 571/4885SMN1; SMN2 95/4885 |
| US-10995086-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, VAPB | NPC1 22/4885RAB9A 2397/4885SMN1; SMN2 2363/4885 |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | NPC1 296/4885RAB9A 571/4885SMN1; SMN2 95/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | NPC1 296/4885RAB9A 571/4885SMN1; SMN2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.